Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yuki Kumihashi"'
Autor:
Takuhiro Yamaguchi, Tempei Miyaji, Takashi Kawaguchi, Kanako Azuma, Taiki Hirata, Ayako Torii, Hiroaki Usui, Soan Kim, Tatsuya Hayama, Daisuke Hirate, Yosuke Kawahara, Yuki Kumihashi, Tomomi Chisaka, Tetsuya Wako, Akinobu Yoshimura
Publikováno v:
BMJ Open, Vol 13, Iss 11 (2023)
Introduction The use of immune checkpoint inhibitors (ICIs) is rapidly expanding in cancer treatment. ICIs have a unique safety profile, characterised by immune-related adverse events (irAEs). The safety profile of ICIs lacks patient experience and p
Externí odkaz:
https://doaj.org/article/d0e6cac28fb4426f91d6091e6c050f7e
Publikováno v:
Journal of Medical Investigation; 2024, Vol. 71 Issue 1/2, p141-147, 7p
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 46(5)
We report three cases of advanced lung cancer with poor PS treated with molecular-targeted drugs and consider the role of cancer chemotherapy to improve quality of life(QOL). Case 1: A 67-year-old woman(PS 3)with multiple liver, bone, and lymph node
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 67:2897-2900
2004年10月より進行,再発大腸癌に対してweekly CPT-11/UFT/LVを9例に施行した.投与スケジュールはCPT-1160mg/m2を第1, 8, 15に外来において点滴静注し,経口薬UFT (300mg/body/日)と経口Leucovorin (75mg/body/日)
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 41(5)
This study evaluated the efficacy and safety of pemetrexed and carboplatin (CBDCA) or cisplatin (CDDP) followed by maintenance pemetrexed for cases of advanced non-squamous non-small cell lung cancer (NSCLC) that were treated in our hospital. Patient